Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The firm is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. The Company’s Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. The Company’s products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and Other. Kyprolis is formulated with Ligand’s Captisol technology. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. Its other products include Pneumosil, Rylaze, Nexterone, Veklury, Zulresso, and Noxafil-IV.